Tafamidis is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Tafamidis was developed by The Scripps Research Institute.
The API has now reached off-patent status, after being launched in 2019.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

According to PharmaTrade, Tafamidis was exported from India in 2023 , with an average price over the period of $28253 /kg.
The key suppliers were MSN Laboratories, with a focus on markets in MEA.

For enquiries regarding more detailed trade data of Tafamidis and many others, contact info@pharmacheminvestor.com